文献速递胸部肿瘤

EGFR C797X突变肺癌的等位基因背景定义四种基因组格局异质性和临床结局不同的亚型

Allelic Context of EGFR C797X-Mutant Lung Cancer Defines Four Subtypes With Heterogeneous Genomic Landscape and Distinct Clinical Outcomes.
PubMed 文献 · J Thorac Oncol · 2023-11-20

在九个中心识别365例奥希替尼进展后EGFR C797X突变NSCLC患者,按等位基因背景分为顺式(75.3%)、反式(6.4%)、顺式&反式(10.4%)和仅C797X(7.9%)四亚型;顺式&反式亚型预后最差,顺式患者后续布格替尼联合西妥昔单抗PFS优于其他方案,且观察到亚型转换。

要点

  • EGFR C797X突变按等位基因背景分为四亚型,比例分别为75.3%、6.4%、10.4%和7.9%。
  • 顺式&反式亚型 concurrent alterations频率最高(21.1%),PFS和OS最差。
  • 顺式患者后续布格替尼联合西妥昔单抗PFS优于其他方案(中位11.0 vs 其他,p=0.005)。

核心结论

  • 等位基因背景可定义四种EGFR C797X突变NSCLC亚型,具有异质性遗传格局和不同临床结局。
  • 后续治疗通过亚型转换进一步使情况复杂化。

研究设计与样本

  • 从九个中心识别奥希替尼进展后EGFR C797X突变NSCLC患者,全部在单一实验室通过下一代测序分析。
  • 共纳入365例EGFR C797X突变病例,分析基因组谱并评估临床结局与C797X状态的关联。

主要发现

  • 365例按等位基因背景分为顺式(75.3%)、反式(6.4%)、顺式&反式(10.4%)和仅C797X(7.9%)四亚型。
  • 顺式&反式亚型在奥希替尼耐药位点 concurrent alterations频率最高(21.1%),顺式亚型最低(8.4%)。
  • 顺式&反式患者既往治疗中位PFS为7.7个月,后续治疗中位PFS为1.0个月,中位OS为3.9个月。
  • 后续治疗中,顺式患者接受布格替尼联合西妥昔单抗的中位PFS为11.0个月,优于其他方案(p=0.005)。
  • 反式患者接受第一或第二代联合第三代EGFR抑制剂的中位PFS为2.6个月(范围0.7-8.1个月)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: EGFR C797X (C797S or C797G) mutation is the most frequent on-target mechanism of resistance to osimertinib. The hypothesis that the allelic context of C797X/T790M has implications for treatment is on the basis of sporadic reports and needs validation with larger cohorts. METHODS: We identified patients with EGFR C797X-mutant NSCLC from nine centers who progressed on osimertinib, all analyzed in a single laboratory through next-generation sequencing. We analyzed genomic profiles and assessed associations between clinical outcomes and C797X status. RESULTS: A total of 365 EGFR C797X-mutant cases were categorized into four subtypes on the basis of allelic context: in cis (75.3%), in trans (6.4%), cis&trans (10.4%), and C797X-only (7.9%). Genomically, the cis&trans subtype displayed the highest frequency of concurrent alterations at osimertinib resistance sites (21.1%), while the in cis subtype had the lowest (8.4%). Clinically, cis&trans patients exhibited the worst progression-free survival (PFS) on both previous (median 7.7 mo) and subsequent treatment (median 1.0 mo) and overall survival (median 3.9 mo). In subsequent treatments, in cis patients exhibited superior PFS with combined brigatinib and cetuximab (median 11.0 mo) compared with other regimens (p = 0.005), while in trans patients exhibited variable outcomes with combined first or second- and third-generation EGFR inhibitor (PFS range: 0.7-8.1 mo, median 2.6 mo). Notably, subtype switching was observed after subsequent treatments, predominantly toward the in cis subtype. CONCLUSIONS: Allelic context could define four EGFR C797X-mutant NSCLC subtypes with heterogeneous genetic landscapes and distinct clinical outcomes. Subsequent treatments further complicate the scenario through subtype switching.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Lu C, Wei XW, Wang Z, et al. Allelic Context of EGFR C797X-Mutant Lung Cancer Defines Four Subtypes With Heterogeneous Genomic Landscape and Distinct Clinical Outcomes. J Thorac Oncol. 2023. PMID: 37981218. doi:10.1016/j.jtho.2023.11.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。